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Abstract
Robust replication of hepatitis C virus (HCV) in cell culture occurs only with the JFH-1 (genotype 2a) recombinant genome.
The aim of this study was to develop a system for HCV infection quantification analysis and apply it for the selection of
patient sera that may contain cell culture infectious viruses, particularly of the most clinically important genotype 1. Initially,
a hepatoma cell line (designated Huh-7.5/EG(4A/4B)GLuc) was generated that stably expressed the enhanced green
fluorescent protein (EGFP) fused in-frame to the secreted Gaussia luciferase via a recognition sequence of the viral NS3/4A
protease. Upon HCV infection, NS3/4A cleaved at its signal and the Gaussia was secreted to the culture medium, thus
facilitating the infection quantification. The Huh-7.5/EG(4A/4B)GLuc cell line provided a rapid and highly sensitive
quantification of HCV infection in cell culture using JFH-1-derived viruses. Furthermore, the Huh-7.5/EG(4A/4B)GLuc cells
were also shown to be a suitable host for the discovery of anti-HCV inhibitors by using known compounds that target
distinct stages of the HCV life cycle; the Z-factor of this assay ranged from 0.72 to 0.75. Additionally, eighty-six sera derived
from HCV genotype 1b infected liver transplant recipients were screened for their in vitro infection and replication potential.
Approximately 12% of the sera contained in vitro replication-competent viruses, as deduced by the Gaussia signal, real time
quantitative PCR, immunofluorescence and capsid protein secretion. We conclude that the Huh-7.5/EG(4A/4B)GLuc cell line
is an excellent system not only for the screening of in vitro replication-competent serum-derived viruses, but also for the
subsequent cloning of recombinant isolates. Additionally, it can be utilized for high-throughput screening of antiviral
compounds.
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Introduction
Hepatitis C virus (HCV), which infects 2–3% of the world’s
population, is a major cause of chronic hepatitis, leading to liver
cirrhosis and hepatocellular carcinoma in a significant portion of
infected patients [1]. HCV is an enveloped positive-strand RNA
virus that belongs to the Flaviviridae family [2]. The genome of
HCV is composed of the 59 non-translating region (59 NTR),
a single open reading frame encoding at least 10 proteins and the
39 NTR. The viral particle is composed of structural proteins, core
(C), and the envelope glycoproteins (E1 and E2). The other non-
structural proteins (NS proteins) include the viroporin ion channel
p7, the NS2–3 protease, the NS3 dual-function protein (serine
protease and helicase), the NS4A polypeptide, the NS5A
phosphoprotein and the NS5B RNA-dependent RNA polymerase
(RdRp) [3]. There are six distinct HCV genotypes and multiple
subtypes [4]; among these genotypes there exist clusters of global
distribution, with types 1a and 1b being the most common,
accounting for about 60% of global infections [5].
In vitro HCV studies advanced through two breakthroughs: first,
subgenomic replicons of subtypes 1b [6,7] and 1a [8], which
replicate autonomously and preferably in selected subclones of the
human hepatoma cell line Huh-7, proved to be highly permissive
for HCV replication; e.g., Huh-7.5 [9] or Lunet cells [10]; second,
the JFH-1 (genotype 2a) isolate, which supports a full infectious
cycle in cell culture [11], as well as in its intra- and inter-genotypic
chimeric derivatives (e.g., the JC1 chimera) [12,13,14]. Although
propagation of HCV in cell culture has been an important
contribution to the field, it is generally recognized that while
subgenomic replicons do exist for a limited number of strains, only
the JFH-1 isolate completes the HCV life cycle in vitro. Hence, the
development of new in vitro replication-competent isolates became
a priority.
Methodologies and detection methods for HCV in vitro infection
have ranged from immunostaining and quantitative PCR to the
use of infectious viruses carrying reporter genes (e.g., Firefly
luciferase or Green Fluorescent Protein [GFP]) [15,16]. Overall,
cell-based assays which depend on viral enzymes appear
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advantageous to those assays that are based on bulk populations in
terms of offering a mean for differentiating between viral and
cellular functions. Lee et al. [17] developed a cell-based assay for
monitoring HCV NS3/4A protease activity in mammalian cells.
Their study described a substrate vector in which the enhanced
GFP (EGFP) was fused to the secreted alkaline phosphatise (SEAP)
through the NS3/4A protease decapeptide recognition sequence,
which spans the NS4A and NS4B junction region (Delta4AB).
Mammalian cells stably expressing the EGFP-Delta4AB-SEAP
cassette enabled the monitoring of NS3/4A activity upon
expression in trans of the protease by subgenomic HCV replicon
transfection. Iro et al. [18], created a Huh7 cell line (designated
Huh7-J20) expressing the identical cassette for rapid and sensitive
quantification of HCV infection in cell culture by JFH-1 or JFH-1
chimeric viruses. Finally, Pan et al et al. [19], generated a similar
stable cell line (designated Huh7.5-EG(D4B5A)SEAP), which is
based on the Huh-7.5 cells and the NS4B-NS5A junction region as
a recognition sequence for the viral protease .
Recently, a real-time imaging of HCV infection using a fluores-
cent cell-based reporter system has been described [20]. In this
system a cellular marker of HCV infection was constructed based
on a known substrate of the NS3/4A protease, the mitochondrially
tethered interferon (IFN)-b promoter stimulator protein 1 (IPS-1).
Huh-7.5 cells stably express a chimeric protein encompassing the
C-terminal region of IPS-1 fused to diverse fluorescence proteins
alone (Fluorescence Proteins-IPS) or via a nuclear localization
sequence (Fluorescence Proteins-NLS-IPS). Chimeric proteins
localization followed a mitochondrial pattern along with the single
IPS-1 localization. Upon JFH-1 infection or replication of
subgenomic replicons of diverse subtypes, expression of the viral
protease lead to the IPS substrate recognition and truncation and
subsequent re-localization of the fluorescent proteins in the whole
cytoplasm or in the nucleus (for those constructs that contained the
NLS). This system allowed the monitoring of HCV infection at
a single cell level by live-cell imaging of viral propagation.
The aim of the present study was to develop a robust and highly
sensitive system for HCV infection quantification analysis. Given
the advantages of the NS3/4A protease systems described above,
we established a new cell line, designated Huh-7.5/EG(4A/
4B)GLuc, which stably expresses the construct described by Lee et.
al. modified as follows: EGFP was fused to the robust Gaussia
luciferase [21] via a recognition sequence for the NS3/4A
protease. The utility of this new system was evaluated not only
in terms of virus entry and replication inhibition by means of JFH-
1 infections and known inhibitors neutralizations, but also for the
screening of clinical sera with the capacity to contain in vitro
replication-competent isolates.
Materials and Methods
Ethics Statement
The Investigation and Ethics Committee of Hospital Clinic
Barcelona approved our protocol, including the use of human
samples, which conformed to the ethical guidelines of the 1975
Declaration of Helsinki. Written informed consent was obtained
from all the patients included in this study.
Cell Culture and Cell Lines
Huh-7.5 [9] (kindly provided by Prof. Charles Rice, The
Rockefeller University, NY, USA), and 293T (HEK293T cells,
American Type Culture Collection, Manassas, VA, CRL-1573)
cells were grown in Dulbecco’s modified Eagle medium (DMEM;
Invitrogen, Carlsbad, CA) supplemented with 2 mM L-glutamine,
non-essential amino acids, 100 U of penicillin per ml, 100 mg of
streptomycin per ml, and 10% fetal calf serum (FCS), designated
DMEM complete, in an incubator with 5% CO2 at 37uC.
Plasmid Construction and Establishment of the Gaussia
Cell Line, Huh-7.5/EG(4A/4B)GLuc
This method is provided in the Supporting Information S1 section.
HCVcc Infections and Neutralizations
JC1 virus was prepared as described [22] and used to
inoculate Huh-7.5/EG(4A/4B)GLuc cells for 4 h previously
seeded in 96 well plates, 1.26104 cells/well. In the case of IFN-
a (Interferon-aA, Sigma-Aldrich, St. Louis, MO), 10 h post-
seeding, cells were washed 1x with PBS and fed with fresh
DMEM complete supplemented with the indicated doses of
IFN-a for 8 h. In the case of anti-receptor inhibitions (anti-
CD81 mouse mAb clone JS-81, BD Pharmingen, San Diego,
CA; or anti-SR-BI, clone C167, kindly provided by Dr. A.
Nicosia), cells were treated with the indicated doses for 1 h
prior to infection. Finally, viruses were incubated with the
indicated amounts of anti-E2 human conformational mAb
AR3A (kindly provided by Dr. M. Law) for 1 h at RT with
gentle agitation prior to inoculation. Infections were performed
always in duplicate wells measured in duplicates (n = 4). Results
are given as percentage relative to control infections as follows:
IFN-a relative to mock infections, anti-CD81 relative to mouse
IgG1 isotype control (clone MOPC-31C, BD Pharmingen, San
Diego, CA, anti-SR-BI and anti-E2 relative to human IgG
(Southern Biotech, Birmingham, AL).
Sera Collection and Inoculations
Eighy-six patients who underwent liver transplantation due to
HCV infection and who presented recurrent hepatitis post-
transplantation were selected. Patient blood was collected in
VacutainerH Rapid Serum Tube (Becton Dickinson, Franklin
Lakes, NJ) and the serum was then separated after centrifugation
at 1,0006g for 10 min. Serum was aliquoted and kept at 280uC.
Viral load was determined by real-time PCR (COBAS TaqMan
HCV Test, Roche Diagnostics, Mannheim, Germany). For
inoculation of Huh-7.5/EG(4A/4B)GLuc cells, sera were thawed
gently at 4uC. DMEM complete was aspirated from cells, which
were washed 3x with PBS. Sera were diluted 1:10, unless otherwise
stated, to DMEM complete without FCS and the DMEM-sera
mix was used to inoculate the cells, in duplicate. Four h post-
inoculation, DMEM-sera mix was aspirated, cells were washed 3x
with PBS, and then fed with DMEM complete with FCS for
120 h.
In vitro Transcription, Electroporation of HCV RNAs,
Generation of HCVcc Stocks, and Determination of Virus
Titers in cell Culture Supernatants
These methods were employed as previously described [22].
Gaussia Luciferase Assay
Cell culture supernatants from Huh-7.5/EG(4A/4B)GLuc cells
were collected and centrifuged at 1,5006g for 10 min and cell-free
supernatants were kept at 4uC until Gaussia luciferase measure-
ments were taken. For each well, 2650 ml supernatant was mixed
with 50 ml Gaussia assay buffer (Gaussia Juice, PJK GmbH,
Kleinblittersdorf, Germany) and then measured for 10 s in an
Orion II Microplate Luminometer (Berthold Detection Systems,
Pforzheim, Germany).
A Gaussia Cell-Based System for HCV Infection
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HCV RNA Quantification by RT-qPCR
Viral RNA was isolated from HCVcc- or sera-inoculated cells
and 25 ng of the total RNA sample was used for RT-quantitative
PCR analysis with 59 NTR-specific probe and primers as
described in Supporting Information S1.
Calculation of S/B, S/N, and Z-factor
To validate the performance of the Huh-7.5/EG(4A/4B)GLuc
cells for HTS assays, the signal-to-noise ratio (S/N), signal-to-
background (S/B) and Z-factor values were calculated using the
methods described by Zhang et. al. [23]. In JC1 replication
inhibition, Huh-7.5/EG(4A/4B)GLuc cells were seeded in 96 well
plates, 1.26104 cells/well and treated with IFN-a (500 U/ml) or
mock-treated as described above, followed by infection with JC1
viruses at an MOI 0.5 TCID50/cell. In JC1 entry inhibition, cells
were seeded as described above. 1 h prior to infection cells were
treated with anti-CD81 or mouse monoclonal control antibodies
(both at 1 mg/ml). For each individual infection condition, 8 wells
were used. At 5 days post infection, Gaussia activity was de-
termined for each well in duplicate and S/B, S/N and Z-factor
values were calculated.
Indirect Immunofluorescence
250 ml of electroporated cells (16105 cells) were seeded on
glass coverslips in 24-well plates. After 72 h, cells were fixed
with 4% paraformaldehyde in PBS and permeabilized with
0.5% Triton X-100 in PBS. In the case of patient sera or JC1
inoculations, cells were infected as described above, and fixed
96 h post inoculation. Immunostaining of NS5A protein was
performed by using the mouse monoclonal 9E10 (kindly
provided by Dr. C. Rice), of E2 protein by the anti-E2 human
conformational mAb AR3A (kindly provided by Dr. M. Law)
and of core by the mouse monoclonal anti-core antibody C7–50
(Santa Cruz Biotechnologies, Santa Cruz, CA), all at a final
concentration of 1 mg/ml in PBS supplemented with 5% bovine
serum albumin (BSA). Bound primary antibodies for the NS5A
or the E2 were detected using goat a-mouse antibodies
conjugated to AlexaFluorH 568 or goat a-human antibodies
conjugated to AlexaFluorH 488 (Invitrogen, Eugene, OR),
respectively, at a dilution of 1:1,000 in PBS with 5% BSA.
DNA was stained with DAPI (49, 6-Diamidino-2-phenylindole
dihydrochloride) (Sigma-Aldrich, St. Louis, MO). Finally, cells
were washed 3x with PBS and once with water and mounted
on glass slides with Fluoromount G (Southern Biotechnology
Associates, Birmingham, AL).
Quantification of HCV Positive Cells
To assess the number of HCV positive cells, cells seeded as
described above were inoculated at various multiplicities of
infection (MOI) for 4 h. Five days post infection, cells were fixed
and the proportion of infected cells was monitored by NS5A-
specific indirect immunofluorescence as described above. For each
infection at least 1,000 cells were evaluated.
Preparation of Cell Lysates, PAGE, and Western Blot
Analysis
In order to prepare cell lysates for Western blot analysis, cells
were lysed with 1% Triton X-100 in PBS. Proteins present in the
cell lysates were separated by SDS-PAGE electrophoresis and
transferred to a PVDF membrane for claudin, occludin, NS3,
core, GFP, b-actin or GAPDH detection. A detailed description of
this method is provided in Supporting Information S1.
Quantification of HCV Core Protein
HCV core protein in cell culture supernatants was quantified
using the OrthoH HCV antigen ELISA test kit (Ortho Clinical
Diagnostics, Tokyo, Japan). Cell culture supernatants were
harvested 120 h post infection, filtered through 0.45-mm-pore-size
filters and kept at 280uC until the day of measurement.
Colorimetric measurements were performed using a Sunrise
colorimeter (Tecan Trading AG, Switzerland).
Statistical Analyses
Data are presented as mean 6 standard deviation (SD). The
statistical comparison between two groups was made by a Mann-
Whitney test. p value , 0.05 was considered to indicate
a significant difference.
Results
Generation of the Huh-7.5/EG(4A/4B)GLuc Cell Line and
Comparison with the Parental Huh-7.5 Cells
To generate a highly sensitive cell-based assay for HCV
infectivity quantification, several reporter plasmids were con-
structed according to the NS3/4A-based reporter assay systems
mentioned in the Introduction section. In our constructs the secreted
alkaline phosphatase (SEAP) was replaced by the humanized form
of the Gaussia luciferase (hGLuc) fused in-frame to the enhanced
green fluorescence protein (EGFP) via various recognition
sequences for the viral NS3/4A protease (Fig. 1A): i. the C-
terminal region of IPS-1, encompassing the NS3/4A recognition
site and a mitochondrial targeting sequence (amino acids 462–540,
IPS452–540) ii. similar to (i) with the addition of an SV40 nuclear
localization sequence (NLS) between the EGFP and the IPS
segment (NLS-IPS462–540) iii. the ER retention signal (defined by
amino acid sequence "KDEL") followed by octapeptide DEDE-
DEDE and the HCV genotype 1b NS4A/4B substrate sequence
DEMEEC-ASHL iv. similar to (iii) without the ER retention
signal.
Initially, these reporter constructs were transiently transfected to
Huh-7.5 cells to examine whether they could be efficiently cleaved
by NS3/4A protease following HCV infection (JC1 chimeric virus,
at an MOI 0.5 TCID50/cell). At 5 days post infection, cell culture
media were harvested and analyzed for Gaussia activity. As shown
in Fig. 1B, elevated Gaussia levels, relative to control infections,
were observed in these media harvested from cells that were
transfected with the EGFP(DE4x-4A/4B)GLuc construct. This
construct was similar to that referred by Iro et. al. [18], although
Pan et. al. [19], failed to detect elevated amounts of SEAP activity
with the same construct in a transient transfection and infection
assay. The lack of success with the other constructs, including the
IPS constructs and the KDEL-DE4x-4A/4B cassette, suggests that
the viral recognition sequence may not be accessible by the NS3/
4A protease caused by different protein conformations when the
various peptide sequences are inserted into the chimera fusion
protein.
Next, Huh-7.5 cells were stably transfected with plasmids
encoding the EGFP(DE4x-4A/4B)GLuc construct, selected for 4
weeks under the pressure of G418 antibiotic and finally sorted for
high EGFP expression, thus generating the Huh-7.5/EG(4A/
4B)GLuc cell line. Expression of the known HCV entry receptors
CD81 [24], SR-BI [25], claudin [26] and occludin [27] in the
Huh-7.5/EG(4A/4B)GLuc cell line proved equal to that of the
parental Huh-7.5 cells (Fig. S1A–C). Similar entry profiles for both
cells were confirmed with infections by HCVpp for various
genotypes (Fig. S1D). HCV replication in the Huh-7.5/EG(4A/
4B)GLuc cell line was assessed by: (i) electroporation of JFH-1
A Gaussia Cell-Based System for HCV Infection
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subgenomic replicons carrying the Firefly luciferase reporter (Fig.
S2A); and by (ii) electroporation of wild-type JFH-1 and the intra-
or inter-genotypic chimeric derivatives, JC1 and Con1/JFH-1,
respectively [13] (Fig. S2B). Both methods demonstrated that
HCV replicates to similar levels in both cell lines, as deduced by
the degree of Firefly luciferase expression in the sub-genomic
replicon assay and by the extent of NS5A and E2 expression in
those cells transfected with full-length viruses.
Determination of the Specificity of the Huh-7.5/EG(4A/
4B)GLuc Cell-based System
To assess the specificity of the Huh-7.5/EG(4A/4B)GLuc cell
line, cells were infected with JC1 virus at an MOI 0.5 TCID50/
cell, and Gaussia activity was determined at different time points.
Concomitantly, cells were infected with supernatant from JFH-1/
DGDD-transfected cells as a negative control [22]. Gaussia activity
acquired in JC1 infected-cells was considered total (specific and
unspecific) while that acquired in the negative control was
regarded as unspecific. Specific signal (total minus unspecific)
increased over the specified time course and reached levels up to
10-fold higher than the unspecific signal 120 h post-infection
(Fig. 2A). To determine the sensitivity of the Huh-7.5/EG(4A/
4B)GLuc cell line and the number of infected cells that produce
Gaussia signal at a given viral concentration, cells were infected
with JC1 viruses at various MOIs; 120 h post infection the Gaussia
activity as well as the number of NS5A positive cells were
measured. As shown in Fig. 2B and Fig. S3, the maximum specific
signal reached a plateau when MOIs $ 0.5 TCID50/cell were
administered, which was corresponded to $75% of positive cells.
For each point in Fig. 2B, any unspecific signal by a DGDD
infection (#10 %) was subtracted.
Correlation of Gaussia Activity with HCV RNA and Protein
Levels
To demonstrate that the Gaussia activity secreted by the Huh-
7.5/EG(4A/4B)GLuc cells correlated with HCV RNA replication
levels, the cell line was infected with JC1 or JFH-1 virus at an MOI
0.5 TCID50/cell. Subsequently, the Gaussia activity released in the
medium and HCV RNA levels were determined side-by-side at
different time points post-infection. As shown in Fig. 3A&B, viral
RNAs peaked around 72 or 96 h post-infection for the JC1 or the
JFH-1 infection respectively, and declined thereafter due to
cellular confluence. However, a time-dependent increase in Gaussia
activity occurred as a result of increasing NS3/4A protease
amounts and Gaussia stability. This result implies that the Gaussia
levels do not directly correlate with virus RNA replication levels.
Notably, although equal virus inocula were used for JC1 and JFH-
1 viruses, an approximately 2-fold higher RNA and Gaussia levels
were detected in the JC1 virus analysis in comparison to JFH-1.
Both viruses posses the JFH-1 RNA replication machinery
(proteins NS3-NS5B) and therefore differences in RNA levels
cannot be explained by higher replication capacity of the JC1
chimeric virus. Previously it has been shown that JC1 and JFH-1
virus replicate to the same extent in Huh7 and Huh7-derived
clones [13]. However, JC1 virus produces a significantly higher
amount of in vitro infectious virus at a more rapid kinetic manner
and thus can spread faster in cell culture. Indeed, as shown in Fig.
S4, at an MOI 0.1 TCID50/cell, JC1 virus spread was faster than
that of JFH-1.
To correlate Gaussia activity with viral protein expression, the
viral intracellular protein (core and NS3) levels and the amount of
EGFP still associated with Gaussia protein, were determined post-
infection with the JC1 virus at the same time points as previously.
As shown in Fig. 3C, the cleavage induction between EG(4A/
4B)GLuc correlated directly to increased NS3 protein levels. These
data suggest that there needs to be a significant accumulation of
NS3/4A post viral replication for efficient Gaussia cleavage and
secretion which occurs at time points not earlier than 72 h post
infection.
Determination of Antiviral-mediated Neutralizations
To determine the capability of the Huh-7.5/EG(4A/4B)GLuc
cell line in antiviral-mediated neutralizations, cells were pre-
treated with replication or entry inhibitors (IFN-a or anti-receptor
Figure 1. Schematic of dual-function reporter vectors used in the HCV NS3/4A protease activity assay. (A) The various recognition sites
of NS3/4A protease, IPS462–540, NLS-IPS462–540, KDEL-DE4x-4A/4B and DE4x-4A/4B were inserted between the EGFP and the humanized Gaussia
luciferase gene by an in-frame fusion. Arrows indicate the NS3/4A cleavage site. Expression of the reporter genes is under the human cytomegalovirus
promoter (CMV) and the selection marker for the generation of the stable cell line is neomycin phosphotrasferase (NeoR). SV40, simian virus 40. (B)
Transiently trasfected Huh-7.5 cells were infected with JC1 virus at an MOI 0.5 TCID50/cell or mock infected with JFH-1/DGDD supernatant. At 5 days
post infection, the medium was harvested and Gaussia activity was measured. Results are expressed as the mean values from duplicate wells,
measured in duplicates, from a representative experiment of 3 (mean 6 SD; n = 4).*, P,0.05.
doi:10.1371/journal.pone.0053254.g001
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antibodies [anti-CD81 or anti-SR-BI], respectively), or viruses
were pre-incubated with the conformational anti-E2 antibody
AR3A [28] prior to infection with JC1 virus at an MOI of 0.5
TCID50/cell. A clear dose-dependent inhibition in Gaussia
secretion was acquired for all inhibitors (Fig. 4A). Specifically,
the half maximal inhibitory concentrations (IC50) for the anti-
Figure 2. Specificity and sensitivity of the Huh-7.5/EG(4A/4B)GLuc reporter system. (A) Cells were infected with JC1 virus at an MOI of 0.5
TCID50/cell or mock (JFH-1/DGDD) infected. At the indicated time points, the Gaussia activity is given. (B) Cells were infected with JC1 virus at various
MOIs (1, 0.5, 0.25, 0.125, 0.0625, 0.03125, 0.015625, 0.0 TCID50/ml) and the specific (total minus unspecific) Gaussia activity for each infection condition
is given 5 days post-infection. In parallel, the quantification of the fraction of infected cells was performed by using indirect immunofluorescence
(NS5A positive cells). Results are expressed as the mean values from duplicate wells, measured in duplicates, from a representative experiment of 3
(mean 6 SD; n = 4).
doi:10.1371/journal.pone.0053254.g002
Figure 3. Correlation between extracellular Gaussia activity and HCV RNA and proteins. Huh-7.5/EG(4A/4B)GLuc cells were infected with
JC1 (A) or JFH-1 (B) viruses at an MOI of 0.5 TCID50/cell. Extracellular Gaussia activity and intracellular RNA were analyzed at the given time points post
infection. (C) Correlation between NS3 and core proteins levels with EG(4A/4B)GLuc cleavage efficiency. Huh-7.5/EG(4A/4B)GLuc cells were infected
like in (A) and at the given time points expression levels of NS3, core and EG(4A/4B)GLuc were analyzed by Western blotting by anti-NS3, anti-core
and anti-GFP antibodies, respectively.
doi:10.1371/journal.pone.0053254.g003
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CD81, anti-SR-BI, anti-E2 antibodies and IFN-a were 0.17, 0.38,
9.46 and 22.3 mg/ml, respectively.
Next, we assessed whether the Huh-7.5/EG(4A/4B)GLuc cells
can be adopted for a high-throughput screening (HTS) assay for
novel anti-HCV agents. For this validation, we calculated the
signal to noise ratio (S/N), signal to background ratio (S/B) and
the Z-factor, in the presence or absence of IFN-a or anti-CD81
antibodies (replication or entry inhibitor, respectively), as de-
scribed by Zhang et. al. [23]. As shown in Fig. 4B, the S/N and S/
B ratio and the Z-factor for IFN-a were 102.82, 8.12 and 0.72,
respectively. Regarding the anti-CD81 antibodies (Fig. 4C), the S/
N, S/B ratio and the Z-factor were 94.17, 7.79 and 0.75,
respectively.
Screening of HCV Positive Sera with the Capacity for in
vitro Replication
We screened 86 sera derived from HCV genotype 1b-infected
liver transplant recipients with respect to their in vitro replication
potential by infecting the Huh-7.5/EG(4A/4B)GLuc cell line and
deducing the Gaussia activity 5 d post-inoculation. The viral load
in these samples ranged from 106 to 108 IU/ml. To facilitate the
Gaussia readout, we set a relative scale of reporter activity;
specifically, Gaussia obtained from cells that were in parallel
infected with JC1 viruses was set to 100 while that obtained from
mock-infected cells (JFH-1/DGDD infections) and/or HCV-
negative sera (HCV neg.) was set to 0. Fig. 5A represents the
results of three independent experiments while Fig. 5B represents
the combined results of these experiments (means). Overall, Gaussia
activity produced by cells infected with patient sera was low in
comparison to that secreted by JC1 infected cells. Mean relative
Gaussia activities for experiments 1, 2 and 3 were similar: 25.67 6
1.035, 23.27 6 1.561 and 24.80 6 1.491, respectively (p = n.s.).
Additionally, although Gaussia activity acquired from cells infected
by few patients in one experiment was significantly higher than the
mean, this result was not reproducible in the next experiment.
Hence, Table 1 summarizes those patients whose Gaussia activity
post infection of Huh-7.5/EG(4A/4B)GLuc cells was $ 40% and
reproducible in 3 experiments (patients also indicated in Fig. 5A).
Worth noting is the fact that the in vitro infection and replication of
serum-derived HCV in Huh-7.5/EG(4A/4B)GLuc cells did not
correlate with the initial HCV serum-viral load; in fact, in vitro
infectivities for high-HCV-containing sera (107–108 IU/ml, pa-
tient no. 67–86) were low.
To prove the specificity of serum infections, Huh-7.5/EG(4A/
4B)GLuc cells were pre-incubated with anti-CD81 antibodies
prior to inoculations with the selected sera presented in Table 1.
As shown in Fig. 6A, JC1 control as well as serum infections were
potently inhibited by anti-CD81 antibodies. To further corrobo-
rate this specificity, cells were inoculated with serial dilutions of
JC1 viruses or sera and the Gaussia activity was monitored 120 h
post infection (Fig. 6B). As expected, the magnitude of Gaussia
activity correlated well with the amount of inoculum, demonstrat-
ing that it reflects the infectious titer in a quantitative manner.
To demonstrate that serum-derived HCV did replicate pro-
ductively in Huh-7.5/EG(4A/4B)GLuc cells, HCV RNA and
Gaussia activity were analyzed at different time points post-
inoculation for 2 patients. As shown in Fig. 7A&B, both
intracellular HCV RNA and extracellular Gaussia activity kinetics
were similar to those obtained by HCVcc infections, indicating
Figure 4. Quantification of HCVcc neutralization and estimates
of statistical parameters of the screening system. (A) Huh-7.5/
EG(4A/4B)GLuc cells were pre-incubated with the indicated doses of
IFN-a, and anti-receptor antibodies (anti-CD81 or anti-SR-BI) or viruses
were pre-incubated with anti-E2 antibodies prior to infections with JC1
virus (MOI 0.5 TCID50/cell). Gaussia specific activity was measured
5 days post-infection. The neutralizing activity is expressed as the
percentage of inhibition, normalized to mock incubations. Results are
from a representative experiment of three independent experiments.
All points represent the mean of duplicate infections measured in
duplicate (mean6 SD, n = 4). (B) Huh-7.5/EG(4A/4B)GLuc cells were pre-
treated with IFN-a (open circles) or mock-treated (closed circles) for
18 h prior to infection with JC1 virus (MOI 0.5 TCID50/cell). 5 days post
infection, Gaussia activity was measured and the statistical parameters
S/N, S/B, and Z-factor were estimated. (C) Huh-7.5/EG(4A/4B)GLuc cells
were infected in the presence of anti-CD81 (open circles) or mouse
monoclonal control antibodies (closed circles). 5 days post infection S/
N, S/B, and Z-factor were estimated similar to (B).
doi:10.1371/journal.pone.0053254.g004
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a productive in vitro replication of serum-derived HCV. Further-
more, immunofluorescence (IF) staining of capsid (core) protein in
inoculated cells was performed (Fig. 7C). Core positive cells for
JC1 infected cells were detectable as early as 24 h post infection
whereas core positive cells for serum-inoculated cells were present
from 72 h post inoculation and thereafter. IF staining 96 h post
inoculation was substantially more intense in the JC1 infected cells.
The less intense core signal in serum-inoculated rather reflects less
RNA replication as deduced by the RT-qPCR data than antigenic
differences by the anti-core antibody or distinct half-life times of
the core molecules. Finally, extracellular core was measured by
core ELISA 120 h post inoculation (Fig. 7D). Huh-7.5/EG(4A/
4B)GLuc cells infected with JC1 viruses presented a significant
core release (,500 fmol/l). Interestingly, cells infected with
patient sera did release measurable core amounts in the
supernatant (,100 fmol/l) suggesting that complete HCV repli-
cation took place in Huh-7.5/EG(4A/4B)GLuc cells post in-
oculation with the patient sera.
Figure 5. Overview of the screening strategy. (A) Eighty-six clinical sera were selected from patients as described in Materials and Methods.
Patients number rise relative to the viral load increase. Relative Gaussia expression scale: Gaussia activity by wells infected in parallel with the JC1
virus at an MOI of 0.5 TCID50/cell was set at 100 while that by JFH-1/DGDD and/or HCV control negative serum (HCV neg.) was set at 0. (A) Results
from 3 representative experiments. Means difference between the experiments were not significant (n.s.). Patients with Gaussia activity $40% are
indicated. (B) Colours were drawn according to the mean of 3 independent experiments. In each experiment duplicate infections were performed
and measured in duplicate (n = 4).
doi:10.1371/journal.pone.0053254.g005
Table 1. List of patients with infectivity $ 40%.
Patient Number Viral Load (IU/ml6106) Infectivitya
7 2.58 42610
14 3.40 4063
15 3.41 5068
18 3.82 4063
19 3.93 47610
20 4.14 52614
23 4.33 4461
24 4.45 4669
33 5.00 4364
35 5.00 4763
aInfectivity is expressed as a percentage (% 6 SD) relevant to that obtained
from cells infected in parallel with JC1 viruses.
doi:10.1371/journal.pone.0053254.t001
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Discussion
In the present study we established a robust Gaussia luciferase
cell line, designated Huh-7.5/EG(4A/4B)GLuc, which is as
permissive as the parental Huh-7.5 cells in terms of HCV
infection and in enabling the rapid and accurate quantification of
HCV infections in cell culture via JFH-1 wild-type- or JFH-1-
derived viruses. We determined the secretion of Gaussia reporter
activity based on the HCV NS3/4A protease activity, as has been
previously described in other NS3/4A-dependent systems
[18,20,29].
Initially, several engineered Gaussia fusion proteins were
constructed with diverse NS3/4A-cleavable peptides of NS3/4A
protease. Out of the 4 constructs examined, only the EGFP(DE4x-
4A/4B)Gluc was functional (Fig. 1). Pan et. al., while developing
their similar dual reporter cell line Huh-7.5/EG(D4B5A)SEAP
[19], checked various cleavable peptides as well, including the 4A/
4B signal sequence utilized in this study. In an EGFP-SEAP
configuration, the 4A/4B cleavage site appeared to be inaccessible
by the viral protease. Indeed, Iro et. al. [18], demonstrated that the
insertion of the octapeptide DEDEDEDE prior to the NS4A/4B
recognition sequence is crucial for a cleavage efficiency enhance-
ment, which appeared also true for our EGFP-Gaussia configura-
tion. Interestingly, we established Huh-7.5/EGFP-IPS and Huh-
7.5/EGFP-NLS-IPS cells lines, similar to Jones et. al. [20]; in these
cells, upon JC1 infection, we observed EGFP re-localization in the
whole cytoplasm or in the nucleus, respectively (data not shown).
Nonetheless, C-terminal Gaussia gene addition to both EGFP-IPS
chimeric configurations appeared ineffective with respect to
specific Gaussia secretion upon JC1 infection, likely due to cleavage
interference caused by different protein conformations.
Our Gaussia-based reporter system appears a better alternative
than the previously reported SEAP cell lines. Indeed, the Huh-
7.5/EG(4A/4B)GLuc cell line combines the advantages of the
previously reported Huh7-J20 and Huh-7.5/EG(D4B5A)SEAP
cell lines while also retaining the unique features of the Gaussia
Figure 6. Specificity of serum infection by CD81-specific neutralizations and sera dilutions. (A) Huh-7.5/EG(4A/4B)GLuc cells were pre-
incubated with CD81-specific (JS-81) antibodies or isotype-matched control antibodies for 1 h prior to infections. Gaussia activity in the anti-CD81
pre-incubated cells (dark blue bars) is expressed as percentage (%) relative to that obtained for the control infections. Control infections are
represented as light blue bars. (B) Huh-7.5/EG(4A/4B)GLuc cells were inoculated with serial dilutions of JC1 viruses, patient sera or control HCV
negative serum. 120 h post infection Gaussia activity in the supernatant of the infected cells was determined. Results for (A) and (B) are expressed as
the mean values from duplicate wells, measured in duplicates, from a representative experiment of 3 (mean 6 SD; n = 4). #Serial dilutions of JC1
virus: MOI at 1, 0.5, 0.25, 0.125, 0.0625 and 0.03125 TCID50/cell.
doi:10.1371/journal.pone.0053254.g006
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reporter. These specialized features can be enumerated: (i) as
Gaussia is naturally secreted into the media, no cell lysis is required
for the detection of its enzymatic activity; (ii) the secreted indicator
function not only permits multiple kinetics experiments using only
one culture through the sequential sampling of the medium, but
also allows the cells to be used for other purposes, such as RNA
extraction, Western blot analysis, and other assays; (iii) Gaussia is
non-toxic and very potent - compared to the humanized forms of
firefly (hFLuc) and Renilla (hRLuc) luciferases expressed under
similar conditions, the humanized form of Gaussia (hGLuc)
generates over a 1000-fold higher bioluminescent signal intensity
from live cells (in concert with their immediate environment) and
over a 100-fold higher intensity from viable cells alone (not
including secreted luciferase) or cell lysates [21]; (iv) Gaussia is
stable in culture medium (with a half-life ,6 d) [30] and samples
can thus be stored at 4uC for several days without any significant
change in its activity levels; (v) it is HCV genotype-independent,
and therefore does not require any genetic modification of the
viral genomes, due to the highly conserved nature of the NS3/4A
recognition sequence [31].
Characterization of the Huh-7.5/EG(4A/4B)GLuc cell line
demonstrated that Gaussia activity in the culture medium
correlated precisely with the virus inoculum (Fig. 2B). In order
to obtain maximum Gaussia sensitivity, however, virus inoculations
should be performed with MOI $ 0.5 TCID50/cell, although
accurate infection quantifications were possible with MOIs as low
as # 0.1 TCID50/ml. This unique characteristic suggests that the
Huh-7.5/EG(4A/4B)GLuc reporter system could be utilized in
studies where small or slowly replicating virus samples could
applied; e.g., in the screening of patient sera for the presence of in
vitro replication-competent isolates. In addition, we also showed
that a 5-day infection assay is the optimal time condition for
achieving significant increased amounts of Gaussia activity in
culture medium (Fig. 2A) although already at day 4 post-infection
Gaussia activity was detectable. This time-frame brings our assay at
the same position like that presented by Iro et. al., and 1 day faster
than that presented by Pan et. al. In contrast, Jones et. al., were able
Figure 7. Productive replication of serum-derived HCV in Huh-7.5/EG(4A/4B)GLuc cells. (A&B) Gaussia activity and intracellular HCV RNA
analysis in Huh-7.5/EG(4A/4B)GLuc cells inoculated with sera derived from patients 20 and 35 at the indicated time points. Results represent the mean
values from duplicate wells, measured in duplicate (for both Gaussia and RNA), from a representative experiment of 3 (mean 6 SD; n = 4) (C)
Intracellular core expression in Huh-7.5/EG(4A/4B)GLuc cells inoculated with the indicated patient sera, JC1 virus or HCV negative Serum (HCV neg.)
as negative control, as detected by core protein IF. Cells were stained with a-core specific antibodies (clone C7–50) and a-mouse Alexa-568
antibodies (red). Cell nuclei were counterstained with DAPI (blue), magnification 100x. (D) Core protein released in the supernatant from Huh-7.5/
EG(4A/4B)GLuc cells infected by the indicated patient sera, JC1 virus or HCV neg. serum as negative control, 120 h post inoculation.
doi:10.1371/journal.pone.0053254.g007
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to monitor HCV infection by fluorescence re-localization in their
Huh-7.5 cells expressing RFP-NLS-IPS construct as early as 10–
12 h post infection. This fluorescence system appeals ideal for live
cell microscopy at a single-cell level, which makes it attractive for
elucidation of viral and cellular mechanisms during HCV life
cycle. Whether that system could be applied for HTS assays needs
to be addressed; microscopy-based HTS have been already
described, though with the demand of costly microscopy apparatus
and computer software.
Gaussia read from Huh-7.5/EG(4A/4B)GLuc cells infected in
the presence of selected inhibitors (IFN-a or entry inhibitors)
demonstrated the potential use of this reporter system for HTS of
entry inhibitors and other antiviral compounds. Estimates of
statistical parameters for a potential screening system exist only in
the study of Pan et. al. In our system, the S/N, S/B ratio and the
Z-factor ranged between 94.17–102.82, 7.79–8.12 and 0.72–0.75,
respectively, clearly superior to the SEAP reporter cell line whose
these parameters ranged between 21.2–34–1, 3.8–3.9 and 0.64–
0.74, respectively.
Since the discovery of HCV in 1989, several researchers have
tried to inoculate cells in vitro using serum-derived HCV. These
efforts involved liver cells as well as cells of non-liver origin
including HeLa, CEM, H9, Jurkat, Molt 3, Molt 4, U937,
P3HR1, Raji and Daudi cells [32]. Although the JFH-1 isolate can
replicate in hepatoma cell lines of human and murine origin [33],
high replication levels can only be achieved in select subclones of
the human hepatoma cell line Huh-7, which are highly permissive
for HCV replication; e.g., Huh-7.5 [9] or Lunet cells [10]. These
cell lines harboured a subgenomic replicon and were ‘‘cured’’ by
IFN-a or a polymerase inhibitor, thereby preserving the high
replication capacity observed in HCV.
In this study, we provide evidence for a productive infection and
replication of the Huh-7.5/EG(4A/4B)GLuc cells by clinical sera
derived by patients who underwent liver transplantation due to
HCV infection and who presented recurrent hepatitis post-
transplantation. Studies on HCV kinetics during and immediately
after LT have shown that, although a rapid drop of HCV viral
load occurs within the initial hours after liver graft reperfusion, the
viral load increases as soon as 12 h after graft reperfusion
exceeding pre-transplantation levels by 1 to 3 months after
transplantation in a significant portion of HCV patients who
undergo liver transplantation [34]. Here, we chose eighty-six sera
harvested 3–6 months post LT from patients with hepatitis C
recurrence. In the transplant setting however, the anti-HCV
response takes place (in most cases) in the context of a nonself
histocompatibility complex, in addition to strong immunosupres-
sion [35]. Additionally, viral load values in transplant patients
exceed pre-LT values by 0.96 log IU/ml [36]. These data argue
for a LT patient-sera selection against sera derived by chronic
patients. Indeed, ,12% of those LT-patient sera contained in vitro
replication-competent viruses, as deduced by the Gaussia signal,
real time quantitative PCR, immunofluorescence and capsid
protein secretion. Nevertheless, this infection was less efficient than
that with recombinant HCV virus produced in cell culture.
Since the initial discovery of the JFH-1 virus and its
extraordinary capacity to support the complete HCV life cycle
in vitro several JFH-1-derived chimeric virus with other isolates
have been described [12,13,14,37,38]. Common characteristic of
these chimeric viruses (except the chimeric virus JC1) is the
requirement of cell culture adaptive mutations that increase virus
titers without affecting replication. This finding was also true for
the initial JFH-1 genome [39,40]. Our RNA and Gaussia kinetic
analyses for JC1, JFH-1 and sera-inoculated cells (Fig. 2 and 6)
suggest that although natural viruses contained in patient sera
were able to infect Huh-7.5/EG(4A/4B)GLuc cells and propagate
in vitro, their replication and spread kinetics are less efficient than
those obtained with the highly in vitro adapted JC1 virus. Sera-
derived HCV appears a weakness rather for in vitro replication
than entry into Huh-7.5 cells (G. Koutsoudakis and X. Forns,
unpublished data) which may cause the major contribution for the
in vitro propagation incompetence. However, our results presented
in Fig. 6 & 7 clearly show a productive infection of Huh-7.5/
EG(4A/4B)GLuc cells by patient sera.
Furthermore, although our extensive efforts to minimize inter-
assay variation which could have been produced by manipulations
of the sera (e.g. multiple freeze-and-thaw cycles) or the Gaussia
assay itself (e.g. maintain the same source of Gaussia substrate), the
results obtained by a single serum infection may vary at a higher
level in comparison to JC1 infections. Indeed, JC1 virus is the
product of a unique clone and it was always prepared fresh;
clinical sera contain a variety of infectious and non-infectious
quasispecies which could produce some extra variation among
experiments. Therefore, in order to confirm our infection results
produced by the initial screening (Fig. 5), in the subsequent
experiments (Fig. 6 & 7) we chose only those sera with the highest
infection capacity accompanied by high inter-assay reproducibil-
ity. Our efforts at the moment concentrate on testing the infectious
progeny release in infection experiments or whether these patient-
derived viruses could establish persistent infection in cell culture.
Assuming that we could be successful in these efforts, we do believe
that we should proceed in cloning new recombinant HCV isolates
which may also posses cell culture adaptive mutations.
Altogether, we believe that our robust, specific, and sensitive
Gaussia cell-based assay, utilizing the Huh-7.5/EG(4A/4B)GLuc
cell line, will facilitate the further screening of in vitro replication-
competent serum-derived viruses, as well as the subsequent cloning
of recombinant HCV isolates. In addition, we believe it will prove
effective for the HTS of entry inhibitors and other antiviral
compounds.
Supporting Information
Figure S1 HCV receptor and HCVpp entry analyses in
Huh-7.5 and Huh-7.5/EG(4A/4B)GLuc cells. (A & B)
Expression of SR-BI and CD81 on the surfaces of Huh-7.5 or
Huh-7.5/EG(4A/4B)GLuc cells, respectively. (C) Occludin and
claudin expression as determined by Western blot. (D) Infectivity
of Huh-7.5 vs. Huh-7.5/EG(4A/4B)GLuc cells with HCVpp.
Results are expressed as the mean values from duplicate wells,
measured in duplicates from a representative experiment of 3
(mean 6 SD; n= 4).
(TIF)
Figure S2 HCV replication analysis in Huh-7.5 and
Huh-7.5/EG(4A/4B)GLuc cells. (A) Firefly luciferase activity
in Huh-7.5 vs. Huh-7.5/EG(4A/4B)GLuc electroporated cells
with the subgenomic replicon RNAs carrying Firefly luciferase as
a reporter. Results are expressed as the mean values from
duplicate wells, measured in triplicate, from a representative
experiment of 3 (mean 6 SD; n= 6). (B) Immunofluorescence
analysis of Huh-7.5/EG(4A/4B)GLuc cells electroporated with
JC1 (panels I to IV), Con1/JFH-1 (panels V to VIII), or JFH-1
(panels IX to XII) or Huh-7.5 cells electroporated with JC1 (panels
XIII to XIV, positive control). Cells were stained with anti-E2
specific antibodies or anti-NS5A specific antibodies and anti-
human Alexa-468 (green) or anti-mouse Alexa-568 (red) anti-
bodies, respectively. Cell nuclei were counterstained with DAPI
(blue), magnification 100x.
(TIF)
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Figure S3 Immunofluorescence analysis of Huh-7.5/
EG(4A/4B)GLuc cells 120 h post infection with JC1
virus. Huh-7.5/EG(4A/4B)GLuc cells were infected with JC1
virus at various MOIs as indicated on each image. Cells were
stained with anti-NS5A specific antibodies and anti-mouse Alexa-
568 (red) antibodies. Cell nuclei were counterstained with DAPI
(blue), magnification 20x.
(TIF)
Figure S4 Immunofluorescence analysis of Huh-7.5/
EG(4A/4B)GLuc cells infected with JC1 or JFH-1 viruses
at an MOI 0.1 TCID50/cell. Cells were infected with JC1 or
JFH-1 viruses and at the indicated time points post infection cells
were stained with anti-NS5A specific antibodies and anti-mouse
Alexa-568 (red) antibodies. Cell nuclei were counterstained with
DAPI (blue), magnification 10x.
(TIF)
Supporting Information S1 Protocols for plasmid con-
struction and establishment of the Gaussia cell line Huh-
7.5/EG(4A/4B)GLuc, HCVpp production and infection,
flow cytometry, transient HCV replication using Firefly
luciferase reporter genomes, HCV RNA quantification
by RT-qPCR and preparation of cell lysates, PAGE, and
Western blot analysis are provided in this section.
(DOC)
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